Core Viewpoint - Pumen Technology's stock closed at 13.78 yuan, with a rolling PE ratio of 20.23 times, significantly lower than the industry average of 53.65 times, indicating potential undervaluation in the medical device sector [1][3]. Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and service of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2]. - The company's main products include medical products, home products, testing equipment, and testing reagents [2]. Recent Achievements - In January 2024, Pumen Technology was awarded the "Smart Health Elderly Care Application Pilot Demonstration - Demonstration Enterprise" by three ministries [2]. - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the "2023 China Corrosion and Protection Society Science and Technology Award" first prize [2]. - Pumen's subsidiary, Guangdong Pumen Biomedical Technology Co., Ltd., was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2]. - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzer" received the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" second prize [2]. Financial Performance - In Q1 2025, Pumen Technology reported revenue of 215 million yuan, a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% [2]. - The company's gross profit margin stood at 64.97% [2]. Market Position - As of March 31, 2025, Pumen Technology had 13,289 shareholders, an increase of 3,464 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1].

金融界消息 截至2025年7月29日收盘，普门科技（688389）报收于13.86元，上涨0.14%，换手率 1.49%，成交量6.37万手，成交金额8793.96万元。 资金流向方面，今日主力资金净流出1840.87万元，占比成交额20.93%。其中，超大单净流出694.14万 元、占成交额7.89%，大单净流出1146.73万元、占成交额13.04%，中单净流出流入651.83万元、占成交 额7.41%，小单净流入1189.04万元、占成交额13.52%。 普门科技最新一期业绩显示，截至2025一季报，公司营业总收入2.15亿元、同比减少29.69%，归属净利 润5368.47万元，同比减少49.93%，扣非净利润4995.98万元，同比减少51.63%，流动比率2.751、速动比 率2.502、资产负债率26.13%。 天眼查商业履历信息显示，深圳普门科技股份有限公司，成立于2008年，位于深圳市，是一家以从事研 究和试验发展为主的企业。企业注册资本42848.573万人民币，实缴资本10061.884万人民币。公司法定 代表人为刘先成。 通过天眼查大数据分析，深圳普门科技股份有限公司共对外投资了17家 ...

Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The main products include medical products, home products, testing equipment, and testing reagents [2] Recent Achievements - In January 2024, Pumen Technology was awarded the "Smart Health and Elderly Care Application Pilot Demonstration - Demonstration Enterprise" by three ministries [2] - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the "2023 China Corrosion and Protection Society Science and Technology Award" first prize [2] - The subsidiary Guangdong Pumen Biomedical Technology Co., Ltd. was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2] - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzer" received the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" second prize [2] Financial Performance - In Q1 2025, the company reported revenue of 215 million yuan, a year-on-year decrease of 29.69% [2] - The net profit for the same period was 53.68 million yuan, down 49.93% year-on-year [2] - The sales gross margin stood at 64.97% [2] Market Position - As of July 24, Pumen Technology's stock closed at 13.82 yuan, with a PE ratio of 20.29, marking a new low in 63 days [1] - The company's total market capitalization is 5.922 billion yuan [1] - In comparison to the medical device industry, which has an average PE of 54.56 and a median of 37.54, Pumen Technology ranks 43rd [1][3] Shareholder Information - As of March 31, 2025, Pumen Technology had 13,289 shareholders, an increase of 3,464 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Group 1 - Shenzhen Pumen Technology Co., Ltd. has recently obtained IVDR CE certification for seven electrochemiluminescence reagent products from T?V S?D Group, which is a significant achievement for the company [1] - The certified products include various prostate-specific antigen kits and other diagnostic assays, which are intended for cancer screening, diagnosis, and monitoring [1] - With the new EU In Vitro Diagnostic Medical Devices Regulation (IVDR), the company has now a total of 27 electrochemiluminescence reagent products certified, enhancing its competitiveness in the EU market [1] Group 2 - The IVDR CE certification allows the company’s products to enter the EU market, which is expected to positively impact the company's future operations [1]

近日，深圳普门科技股份有限公司（以下简称"公司"）的 7 项电化学发 光试剂产品获得欧盟公告机构 TÜV 南德意志集团签发的 IVDR CE 认证。具体 情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2025-058 深圳普门科技股份有限公司 关于自愿披露公司产品获得IVDR CE认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据欧盟体外诊断医疗器械法规的规定，本次获得 IVDR CE 认证的产品已 经具备进入欧盟市场的必要条件，有利于进一步提升公司体外诊断产品在欧盟 市场的综合竞争力，对公司未来的经营将产生积极影响。 三、风险提示 本次获得 IVDR CE 认证，仅代表公司相关产品获得欧盟市场的准入资格， 产品的实际销售情况取决于未来市场的推广效果，目前尚无法预测其对公司未 来业绩的具体影响。敬请投资者理性投资，注意投资风险。 特此公告。 深圳普门科技股份有限公司董事会 2025年7月23日 2 / 2 | 序 | 产品名称 | 分类 | 证书 | 预期用途 | | --- | --- ...

普门科技公告，近日公司7项电化学发光试剂产品获得欧盟公告机构T V南德意志集团签发的IVDR CE 认证。 ...

Group 1 - The core viewpoint of the news highlights that DingSa Investment has conducted research on a listed company, focusing on its recent product developments and market strategies [1] - Pumen Technology has received CE certification for its fully automated chemiluminescence immunoassay analyzers eCL8600 and eCL8800, which are now available in international markets, enhancing the company's competitiveness in the global in vitro diagnostics sector [1] - The mid-speed luminescence products are designed to meet the needs of secondary hospitals in China, aiming to serve the basic healthcare market [1] Group 2 - In June, Pumen Technology's carbon dioxide laser treatment machine obtained domestic Class III medical device registration, indicating its capability to treat various skin conditions and its unique position in the aesthetic medical device market [1] - The company plans to continue investing in research and development to expand its portfolio of optical aesthetic medical products, aligning with consumer demands [1] - DingSa Investment, established in March 2012, has a strong track record in asset management and has received multiple awards for its performance in the private equity sector [2]

Group 1 - The core business of the company includes research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The company achieved a revenue of 215 million yuan in Q1 2025, representing a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% year-on-year, with a gross profit margin of 64.97% [2] - The company has received multiple awards, including the "Smart Health Elderly Care Application Pilot Demonstration Enterprise" honor and the "2023 China Corrosion and Protection Society Science and Technology Award" [2] Group 2 - The company's current price-to-earnings (PE) ratio is 19.22, which is significantly lower than the industry average of 51.58 and the industry median of 37.46 [3] - The total market capitalization of the company is 5.609 billion yuan [1] - As of Q1 2025, there are 7 institutions holding shares in the company, with a total holding of 39.11 million shares valued at 588 million yuan [1]

Overview - The core point of the announcement is the progress of the capital increase and related transactions of Shenzhen Pumen Technology Co., Ltd.'s wholly-owned subsidiary, Shenzhen Pumen Biotechnology Co., Ltd. The capital increase aims to enhance the subsidiary's financial strength and competitiveness in the consumer health sector [1][4]. Group 1: Capital Increase Details - The company approved a capital increase of 33 million RMB for its subsidiary, with the total investment from related parties reduced from 64.02 million RMB to 24.20 million RMB [1]. - The registered capital of Pumen Biotechnology will increase from 3 million RMB to 63.20 million RMB, changing the company's ownership from a wholly-owned subsidiary to a controlling subsidiary with a 56.96% stake [1][3]. Group 2: Shareholder and Management Involvement - The management is authorized to handle all matters related to the capital increase, including adjusting contributions from employee stockholding platforms and managing the partnership agreements [2]. - The capital increase involves several stakeholders, including directors, executives, and employee stockholding platforms, to create a long-term incentive system [3]. Group 3: Impact on the Company - The capital increase is expected to promote the development of the consumer health business, meet the funding needs of Pumen Biotechnology, and enhance the overall capital strength and competitiveness of the subsidiary [3]. - The transaction is structured to ensure fairness and will not adversely affect the company's financial status or independence [4].

证券代码：688389 证券简称：普门科技 公告编号：2025-057 深圳普门科技股份有限公司 关于全资子公司增资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次增资暨关联交易事项概述 截至本公告出具日，普门生物已与各投资方签署增资相关文件，并完成本次 增资的相关工商变更登记手续，领取了深圳市市场监督管理局换发的《营业执照》， 变更后的《营业执照》相关信息如下： 企业名称：深圳普门生物科技有限公司 类型：有限责任公司 法定代表人：曾映 注册资本：6320 万人民币 成立日期：2016 年 04 月 12 日 深圳普门科技股份有限公司（以下简称"普门科技"或"公司"）于 2025 年 3 月 30 日召开第三届董事会独立董事第三次专门会议，于 2025 年 4 月 9 日召开第 三届董事会第十五次会议、第三届监事会第十四次会议，于 2025 年 5 月 7 日召开 2024 年年度股东大会，审议通过了《关于变更全资子公司增资方案暨关联交易的 议案》，同意公司变更与关联人共同对全资子公司深圳普门 ...